|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TENM1 |
Gene summary for TENM1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TENM1 | Gene ID | 10178 |
| Gene name | teneurin transmembrane protein 1 | |
| Gene Alias | ODZ1 | |
| Cytomap | Xq25 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9UKZ4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10178 | TENM1 | NAFLD1 | Human | Liver | NAFLD | 4.11e-09 | 9.67e-01 | -0.04 |
| 10178 | TENM1 | S43 | Human | Liver | Cirrhotic | 2.30e-06 | -1.83e-01 | -0.0187 |
| 10178 | TENM1 | HCC1_Meng | Human | Liver | HCC | 7.26e-19 | -1.23e-01 | 0.0246 |
| 10178 | TENM1 | HCC2_Meng | Human | Liver | HCC | 5.01e-07 | -1.83e-01 | 0.0107 |
| 10178 | TENM1 | cirrhotic1 | Human | Liver | Cirrhotic | 1.05e-05 | -1.83e-01 | 0.0202 |
| 10178 | TENM1 | cirrhotic2 | Human | Liver | Cirrhotic | 2.30e-06 | -1.83e-01 | 0.0201 |
| 10178 | TENM1 | cirrhotic3 | Human | Liver | Cirrhotic | 2.51e-02 | -1.83e-01 | 0.0215 |
| 10178 | TENM1 | HCC1 | Human | Liver | HCC | 3.93e-02 | 2.95e+00 | 0.5336 |
| 10178 | TENM1 | HCC2 | Human | Liver | HCC | 4.46e-06 | 2.93e+00 | 0.5341 |
| 10178 | TENM1 | Pt13.a | Human | Liver | HCC | 2.30e-06 | -1.83e-01 | 0.021 |
| 10178 | TENM1 | Pt14.d | Human | Liver | HCC | 2.30e-06 | -1.83e-01 | 0.0143 |
| 10178 | TENM1 | male-WTA | Human | Thyroid | PTC | 3.28e-16 | 2.89e-01 | 0.1037 |
| 10178 | TENM1 | female-WTA | Human | Thyroid | PTC | 2.08e-02 | 2.87e-01 | 0.0726 |
| 10178 | TENM1 | PTC01 | Human | Thyroid | PTC | 2.00e-43 | 9.15e-01 | 0.1899 |
| 10178 | TENM1 | PTC03 | Human | Thyroid | PTC | 1.10e-12 | 5.51e-01 | 0.1784 |
| 10178 | TENM1 | PTC04 | Human | Thyroid | PTC | 6.01e-94 | 1.81e+00 | 0.1927 |
| 10178 | TENM1 | PTC05 | Human | Thyroid | PTC | 9.48e-35 | 1.20e+00 | 0.2065 |
| 10178 | TENM1 | PTC06 | Human | Thyroid | PTC | 1.45e-58 | 1.42e+00 | 0.2057 |
| 10178 | TENM1 | PTC07 | Human | Thyroid | PTC | 8.07e-80 | 1.39e+00 | 0.2044 |
| 10178 | TENM1 | ATC13 | Human | Thyroid | ATC | 2.29e-02 | 7.26e-02 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00181055 | Liver | NAFLD | peptidyl-serine phosphorylation | 63/1882 | 315/18723 | 7.45e-08 | 6.60e-06 | 63 |
| GO:00182094 | Liver | NAFLD | peptidyl-serine modification | 64/1882 | 338/18723 | 4.65e-07 | 2.89e-05 | 64 |
| GO:00070157 | Liver | NAFLD | actin filament organization | 78/1882 | 442/18723 | 5.44e-07 | 3.21e-05 | 78 |
| GO:19029037 | Liver | NAFLD | regulation of supramolecular fiber organization | 66/1882 | 383/18723 | 8.97e-06 | 2.96e-04 | 66 |
| GO:00512227 | Liver | NAFLD | positive regulation of protein transport | 55/1882 | 303/18723 | 1.07e-05 | 3.35e-04 | 55 |
| GO:00458606 | Liver | NAFLD | positive regulation of protein kinase activity | 65/1882 | 386/18723 | 2.22e-05 | 6.13e-04 | 65 |
| GO:00329707 | Liver | NAFLD | regulation of actin filament-based process | 66/1882 | 397/18723 | 2.92e-05 | 7.72e-04 | 66 |
| GO:19049517 | Liver | NAFLD | positive regulation of establishment of protein localization | 55/1882 | 319/18723 | 4.79e-05 | 1.14e-03 | 55 |
| GO:19029057 | Liver | NAFLD | positive regulation of supramolecular fiber organization | 40/1882 | 209/18723 | 4.88e-05 | 1.15e-03 | 40 |
| GO:00336747 | Liver | NAFLD | positive regulation of kinase activity | 74/1882 | 467/18723 | 5.16e-05 | 1.19e-03 | 74 |
| GO:00329567 | Liver | NAFLD | regulation of actin cytoskeleton organization | 60/1882 | 358/18723 | 5.20e-05 | 1.20e-03 | 60 |
| GO:01100537 | Liver | NAFLD | regulation of actin filament organization | 49/1882 | 278/18723 | 6.88e-05 | 1.46e-03 | 49 |
| GO:00313465 | Liver | NAFLD | positive regulation of cell projection organization | 57/1882 | 353/18723 | 2.19e-04 | 3.73e-03 | 57 |
| GO:00432547 | Liver | NAFLD | regulation of protein-containing complex assembly | 66/1882 | 428/18723 | 2.83e-04 | 4.53e-03 | 66 |
| GO:00512587 | Liver | NAFLD | protein polymerization | 49/1882 | 297/18723 | 3.54e-04 | 5.36e-03 | 49 |
| GO:00903166 | Liver | NAFLD | positive regulation of intracellular protein transport | 29/1882 | 160/18723 | 1.24e-03 | 1.41e-02 | 29 |
| GO:00322717 | Liver | NAFLD | regulation of protein polymerization | 38/1882 | 233/18723 | 1.90e-03 | 1.93e-02 | 38 |
| GO:00081547 | Liver | NAFLD | actin polymerization or depolymerization | 36/1882 | 218/18723 | 1.98e-03 | 1.98e-02 | 36 |
| GO:00514957 | Liver | NAFLD | positive regulation of cytoskeleton organization | 37/1882 | 226/18723 | 2.02e-03 | 2.00e-02 | 37 |
| GO:0033135 | Liver | NAFLD | regulation of peptidyl-serine phosphorylation | 26/1882 | 144/18723 | 2.28e-03 | 2.19e-02 | 26 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TENM1 | SNV | Missense_Mutation | novel | c.5350C>G | p.Gln1784Glu | p.Q1784E | Q9UKZ4 | protein_coding | deleterious(0) | benign(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TENM1 | SNV | Missense_Mutation | novel | c.4531C>T | p.Pro1511Ser | p.P1511S | Q9UKZ4 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TENM1 | SNV | Missense_Mutation | c.1030G>A | p.Gly344Ser | p.G344S | Q9UKZ4 | protein_coding | deleterious(0) | probably_damaging(0.918) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TENM1 | SNV | Missense_Mutation | novel | c.2032N>T | p.Val678Leu | p.V678L | Q9UKZ4 | protein_coding | tolerated(0.37) | benign(0) | TCGA-AP-A1DO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TENM1 | SNV | Missense_Mutation | novel | c.7283N>T | p.Ala2428Val | p.A2428V | Q9UKZ4 | protein_coding | tolerated(0.09) | benign(0.057) | TCGA-AP-A1DR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| TENM1 | SNV | Missense_Mutation | c.7614N>T | p.Lys2538Asn | p.K2538N | Q9UKZ4 | protein_coding | tolerated(0.35) | benign(0.13) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TENM1 | SNV | Missense_Mutation | rs749596467 | c.4255N>A | p.Asp1419Asn | p.D1419N | Q9UKZ4 | protein_coding | deleterious(0.01) | benign(0.248) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TENM1 | SNV | Missense_Mutation | novel | c.2316N>G | p.Asn772Lys | p.N772K | Q9UKZ4 | protein_coding | deleterious(0.01) | benign(0.395) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TENM1 | SNV | Missense_Mutation | novel | c.800N>A | p.Ser267Tyr | p.S267Y | Q9UKZ4 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TENM1 | SNV | Missense_Mutation | c.4210N>T | p.Arg1404Trp | p.R1404W | Q9UKZ4 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |